Noom Med Review 2026: Best Behavioral GLP-1 Support — But Is It Worth It?

This Noom Med review applies our independent 25/30/20/25 scoring methodology to one of the most recognizable brands in digital weight loss. Our Noom Med review finds a 7.3/10 — a solid program anchored by Noom's established behavioral coaching platform, the strongest patient experience we have seen in this category, and a $129/mo ongoing rate. The central question this Noom Med review answers has changed since we first wrote it: we had reported Noom as a bundled price covering medication and coaching together. It is not. Noom's own pricing page states that "the cost of medication is not included", so the real question is whether the coaching layer justifies a platform fee paid on top of what you spend on the drug.

Short answer: Noom Med is a legitimate GLP-1 telehealth program that adds a meaningful behavioral coaching layer on top of the standard prescription pathway. Its patient experience is among the best in our 29-provider ranking — Noom's consumer-software roots show. But at $129/mo — with medication on top, not included — a 7.0/10 clinical score and no brand-name GLP-1 access, it is not directly comparable to Yucca Health ($125/mo, 7.5/10) or Gala Health ($179/mo, 6.8/10), whose figures cover the medication. Noom's true monthly total is $129 plus whatever the drug costs, which the page does not publish.

Independent Editor · Scores based on our editorial policy · Verified 2026-07-21 · Independently researched

What Is Noom Med? (Noom Med Review Background)

Noom started as a psychology-based behavioral change app — one of the first digital health companies to apply cognitive behavioral therapy principles to weight management at scale. Over 50 million people have used the broader Noom platform globally. Noom Med is the company's prescription GLP-1 medication layer built on top of that behavioral infrastructure.

The Noom Med model works like this:

1. Intake combining a detailed health history and the Noom behavioral assessment
2. Review by a U.S.-licensed prescriber (not necessarily an obesity-medicine specialist — Noom's clinical identity is behavioral, not subspecialty)
3. Compounded semaglutide or tirzepatide from a licensed 503A compounding pharmacy, shipped to your door
4. Daily Noom behavioral curriculum running in parallel — lessons on food psychology, habit formation, stress-eating patterns, and the behavioral factors that determine whether pharmacotherapy is sustained long-term
5. Ongoing check-ins integrating medication response with behavioral progress

This model is genuinely differentiated from most GLP-1 telehealth. Programs like Gala Health, Wellorithm, and Yucca Health deliver the prescription and clinical monitoring — Noom Med does all of that while also structured daily behavioral programming designed around the same methodology that built a 50-million-user platform.

What Noom Med is not: a specialist clinical service (clinical score 7.0/10), a brand-name GLP-1 provider, or the best-value compounded GLP-1 program in our ranking.

How Much Does Noom Med Cost in 2026?

The most common question in any Noom Med review: what does it actually cost?

Noom Med charges $79 for the first month, then $129/month on the quarterly plan — verified 28 August 2026 directly on Noom's own pricing page, which lists tiers from $39 to $299/mo depending on plan length.

Correction: earlier versions of this review said approximately $149/mo and described the price as bundled, covering medication and coaching together. Both were wrong. The $149 came from secondary health-journalism reporting rather than Noom, and appears nowhere on Noom's site. And Noom's pricing page states plainly: "The cost of medication is not included." We now cite the clinic's own page, which is the standard we should have applied first.

Before completing intake, the pricing realities to understand:

The $129 is the platform, not the drug. Because medication is billed separately, titration toward maintenance doses raises your medication spend on top of an unchanged $129 platform fee. The $79 first month is an intro rate, not the ongoing cost.

Unbundled pricing makes the total harder to know in advance. The $129 buys the platform and clinical oversight; the medication is a separate line Noom does not publish. That means you cannot total your monthly cost before enrolling — the opposite of the all-inclusive providers in our ranking, and the reason Noom is excluded from our price scoring rather than ranked against them on a number that is not comparable.

Brand-name GLP-1 is not available through Noom Med. If you have insurance covering Wegovy or Zepbound and want a telehealth platform that can prescribe the brand-name medication, Noom Med is not the right fit. The one provider in our ranking with full brand-name GLP-1 access is Wellorithm ($147/mo, 8.3/10).

Noom Med pricing vs comparable programs:

⚠️ Disclosure: We have active affiliate partnerships with Gala Health, Wellorithm, and Oak. We receive no commission from Noom Med; this is an independent editorial review. Our scores derive entirely from our editorial policy — commission has never influenced a score on this site.

Noom Med Review: Patient Experience (Their Real Differentiator)

Patient experience is not one of the four criteria we score — we dropped it in August 2026 because what could be verified in it duplicated clinical oversight and transparency, and the rest was unverifiable marketing claim (see our editorial policy). It is still where our Noom Med review finds the clearest case for the service, so we describe it rather than score it. On this dimension Noom is the strongest platform in our 29-provider ranking, alongside Hims & Hers.

What that looks like in practice:

Consumer-grade software built by a consumer-software company. Noom has spent a decade building a mobile experience around habit change and behavioral engagement. The result is a product that feels like a consumer app — not a clinical portal bolted onto a pharmacy operation. Daily lesson content is structured, personalized, and built around behavioral psychology. Push notifications are calibrated for engagement without feeling intrusive. The interface for tracking food, activity, and medication is integrated in a way that most healthcare-adjacent apps struggle to achieve.

Structured daily curriculum. Most GLP-1 telehealth platforms focus on the prescription pathway and clinical follow-up — the behavioral component, if present at all, is a PDF or a generic coaching session. Noom Med's daily curriculum is its founding product: psychology-informed lessons on emotional eating, stress responses, food relationships, and the behavioral patterns that drive weight regain after stopping pharmacotherapy. This is not a cosmetic feature.

Large and active community. The broader Noom ecosystem gives Noom Med users access to one of the largest digital weight-loss communities in the world. For patients who benefit from peer accountability and shared experience — a real factor in long-term adherence — this is meaningful infrastructure that a standalone compounded-GLP-1 program cannot replicate.

High patient satisfaction. Noom's track record on behavioral weight management predates GLP-1 by years; the ratings ecosystem for the platform is well-established. Patients who enter Noom Med knowing what they're buying — behavioral program + medication — consistently rate the experience highly.

Where it falls short: the integration between the medication management layer and the behavioral platform, while better than most competitors, still has seams. The clinical check-ins feel more pharmaceutical than behavioral; the physician doesn't appear inside the behavioral curriculum. Noom's clinical credentialing for the medication side (7.0/10) is also visible to patients who want specialist depth.

Noom Med Review: Clinical Oversight (7.0/10)

Clinical oversight accounts for 30% of our total score and is where Noom Med's scoring gap with our top affiliate partners becomes most visible. Noom Med earns 7.0/10 on clinical quality — adequate, with licensed U.S. prescribers and standard pharmacy infrastructure, but not the subspecialty-level clinical model that distinguishes Mochi Health (8.5/10 clinical) or the high-throughput clinical infrastructure of Henry Meds (8.5/10 clinical).

What Noom Med provides clinically:

• U.S.-licensed prescribers conducting the GLP-1 intake assessment
• Licensed 503A compounding pharmacy for medication dispensing
• Standard compounded-GLP-1 protocols: semaglutide and tirzepatide
• Ongoing clinical follow-up available as part of the program

What Noom Med is not:

• An obesity-medicine subspecialty practice (Noom's clinical identity is behavioral, not physician-led obesity medicine)
• A high-volume clinical infrastructure with 24-hour prescription turnaround like Henry Meds or Gala Health
• A provider with brand-name GLP-1 prescribing capability

For most patients starting GLP-1 therapy for the first time — with a clear medical history and uncomplicated eligibility — the 7.0/10 clinical score is sufficient. The prescribers are licensed, the pharmacy is compliant, and the protocol is standard. Where the score gap matters: patients with complex medical histories, prior GLP-1 attempts that failed at standard ramp protocols, or specific needs for obesity-medicine expertise will find more clinical depth at Mochi Health or in-person weight-management programs.

The FDA's current guidance for patients considering compounded GLP-1 medications is available at fda.gov.

Noom Med Review: Treatment Options (7.0/10)

Noom Med's treatment menu earns a 7.0/10 — the compounded semaglutide and tirzepatide options are standard, and the behavioral curriculum is a genuine add, but the absence of brand-name GLP-1 and oral/sublingual formats limits the score.

What they offer:

• Compounded semaglutide — injectable, the core medication product
• Compounded tirzepatide — available as an alternative or for patients who need the dual GIP/GLP-1 mechanism
• Noom behavioral coaching platform — daily curriculum, community, habit tracking (the genuine differentiator)

What they don't offer:

• Brand-name Wegovy or Zepbound (compounded only)
• Oral or sublingual semaglutide formats
• Multi-vertical telehealth (hair, ED, NAD+) under one account — Noom Med is weight-loss focused

For patients considering compounded vs brand-name GLP-1, the relevant framework is in: Compounded vs Brand Semaglutide: Cost, Safety & How to Choose.

Noom Med Review: Transparency and Trust (8.0/10)

Noom Med earns 8.0/10 on transparency — a strong score driven by the company's public track record, established brand, and clear pricing disclosure. A publicly-traded behavioral health company (Noom, Inc.) adding a prescription layer carries meaningful institutional accountability that pure-play telehealth startups don't.

Positive signals:

• Noom is an established brand with multi-year operating history in digital health — not a pop-up GLP-1 telehealth
• Pricing is bundled but publicly disclosed before intake (unlike some programs that require completing health history to see any numbers)
• Compounding pharmacy partnership is disclosed; the not-FDA-approved disclaimer for compounded medications is present
• Public company track record and platform transparency (50M+ user history) provides institutional credibility

Limitations:

• Clinical partner details — exactly which prescribers or pharmacy networks fulfill Noom Med — are not as prominently disclosed as platforms with named LegitScript listings or 503A pharmacy identities on their site
• The bundled pricing model, while honest, makes direct medication-cost comparison harder for patients trying to evaluate cost vs standalone programs
• Oral/sublingual options are not publicly confirmed as available

For guidance on vetting any GLP-1 program — including the specific signals that separate legitimate programs from risky ones — see our GLP-1 safety guide.

Noom Med Review vs Our Top-Rated Partners

The central finding of this Noom Med review: Noom's differentiated offering is real, but at $149/mo it costs less than Gala Health's weight-loss program (7.4/10, $179/mo) and more than our value picks.

Noom Med's patient experience is genuinely the strongest reason to consider it — and for patients who've tried GLP-1 without behavioral structure and found themselves stopping when the medication was stopped, that structure matters. But Gala Health delivers a 7.4/10 overall — driven by stronger clinical and treatment scores — for $30/mo more. Wellorithm undercuts Noom by $2/mo and adds full brand-name GLP-1 access.

The behavioral coaching is the value proposition; the clinical program is table stakes. For patients who want the Noom behavioral system specifically and are willing to pay $149/mo for the bundled package, Noom Med is a real option. For patients whose priority is best-overall-score or brand-name GLP-1 access, our affiliate partners are the better fit.

For direct side-by-side comparisons: Wellorithm vs Noom Med · Noom Med vs Gala Health · Mochi Health vs Noom Med.

Who Should Choose Noom Med?

Despite our finding that most patients get a higher clinical score for the same or less money with our affiliate partners, Noom Med is the right fit for a specific patient profile:

Good fit if:

• You've tried GLP-1 before without behavioral support and found yourself regaining weight when you stopped medication — Noom's curriculum specifically addresses the behavioral side of long-term adherence
• You're a former Noom behavioral program user who wants to add GLP-1 medication within the same platform ecosystem you already trust
• You want the most polished digital experience in this category — the best we have seen in this ranking — and are willing to accept the clinical score trade-off
• You want compounded GLP-1 medication bundled with structured behavioral coaching and are not seeking brand-name access

Better alternatives if:

• You want a higher overall score with a broader menu → Gala Health ($179/mo, 6.8/10) delivers stronger clinical and treatment dimensions
• You want brand-name GLP-1 (Wegovy, Zepbound, Mounjaro) → Wellorithm ($147/mo, 8.3/10) is the only provider in our ranking with full brand-name GLP-1 access at a price below Noom Med
• You want the best clinical quality for the money → Yucca Health ($125/mo, 7.5/10, 4.6/5 Trustpilot) delivers higher clinical quality at $3/mo less
• You want the lowest entry price → Oak ($119/mo, 7.7/10, no subscription lock-in) is $16/mo less with a higher overall score

Frequently Asked Questions About Noom Med Review

Yes. Noom Med is a legitimate GLP-1 telehealth program operated by Noom, Inc., one of the largest digital health companies in the behavioral weight-loss space. They work with U.S.-licensed prescribers and licensed 503A compounding pharmacies. Compounded semaglutide and tirzepatide are not FDA-approved drugs, but the prescribing and dispensing process is legal under current 503A pharmacy rules. The behavioral coaching platform is Noom's established product with over a decade of public history.

Noom Med's compounded GLP-1 program starts at approximately $149/mo based on health journalism reporting from 2025–2026. This is a bundled price that includes both the medication and access to Noom's behavioral coaching platform. Compounded tirzepatide costs more. Full tier pricing may require completing intake to surface. For comparison: Gala Health is $179/mo (6.8/10), Yucca Health is from $146/mo (7.5/10), and Oak is $119/mo (7.7/10). See all-in prices at /cheapest.

No. Noom Med currently provides compounded semaglutide and tirzepatide — not brand-name Wegovy, Zepbound, Mounjaro, or Ozempic. If you have insurance coverage for brand-name GLP-1 or want a telehealth platform that can prescribe Wegovy or Zepbound, Wellorithm ($147/mo, 8.3/10) is the one provider in our 29-provider ranking that offers full brand-name access alongside compounded options.

Noom Med scores 7.3/10 in our ranking; Wellorithm scores 8.3/10 and Gala Health scores 7.4/10. Gala Health's weight-loss program costs $30/mo more than Noom Med but delivers higher clinical (8.0 vs 7.0) and treatment (9.0 vs 7.0) scores. Wellorithm is $2/mo cheaper than Noom Med and adds full brand-name GLP-1 access. Noom Med's advantage is its patient experience and the integrated behavioral coaching curriculum — a genuine differentiator for patients who want structured behavior-change programming alongside their prescription. See: Wellorithm vs Noom Med and Noom Med vs Gala Health.

Our Top Picks for GLP-1 Weight Loss

This Noom Med review finds a 7.3/10 program with the best patient experience in its price tier and a genuine behavioral coaching differentiator. For most patients, however, our affiliate partners deliver a higher overall score at the same or lower monthly cost.

If you're ready to start:

⚠️ Medical disclaimer: Compounded semaglutide and tirzepatide are not FDA-approved drugs. They are prepared by licensed 503A compounding pharmacies under a valid prescription. Always consult a licensed healthcare provider to determine whether GLP-1 medication is appropriate for your medical history. This review is for informational purposes only and does not constitute medical advice.

⚠️ Affiliate disclosure: We earn a commission when you use our links to Gala Health, Wellorithm, and Oak. We do not earn a commission from Noom Med — this is an independent editorial review. Our scoring methodology is independent of commercial relationships. See our affiliate disclosure and editorial policy.

Last updated: August 2026 · Prices sourced from public health journalism (Healthline, Forbes Health, CNBC 2025–2026); direct re-verification pending next Weekly Maintenance.

Related Reading

• Best Online Semaglutide Providers 2026 — Full Ranking
• Semaglutide vs Tirzepatide: Which Is Right for You?
• Compounded vs Brand Semaglutide: Cost, Safety & How to Choose
• Is Compounded Semaglutide Still Legal in 2026?
• GLP-1 Weight Loss Cost in 2026: All-In Prices Compared
• Zepbound Insurance Coverage in 2026: Which Plans Pay?
• Gala Health Review 2026
• Wellorithm Review 2026
• Yucca Health Review 2026
• Oak Review 2026